Protein farnesyltransferase · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Protein farnesyltransferase shows approved-linked disease relevance led by Hutchinson-Gilford progeria syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P49354. Start with Hutchinson-Gilford progeria syndrome, then reuse UniProt P49354 as the stable protein anchor across project notes and exports.
Start with Hutchinson-Gilford progeria syndrome, then reuse UniProt P49354 as the stable protein anchor across project notes and exports.
Protein farnesyltransferase shows approved-linked disease relevance led by Hutchinson-Gilford progeria syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Hutchinson-Gilford progeria syndrome because it currently carries approved-linked support. Linked drugs include LONAFARNIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha
Review this target as Protein farnesyltransferase, mapped to UniProt P49354. ChEMBL maps the protein component as Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha. Sequence length is 379 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Protein farnesyltransferase as ChEMBL target CHEMBL2094108, mapped to UniProt P49354. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Protein farnesyltransferase is the right protein anchor across sources, using UniProt P49354 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Hutchinson-Gilford progeria syndrome is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Protein farnesyltransferase |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P49354 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha |
| UniProt Accession | P49354 |
| Component Type | Protein |
| Sequence Length | 379 aa |
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha
Review this target as Protein farnesyltransferase, mapped to UniProt P49354. ChEMBL maps the protein component as Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha. Sequence length is 379 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Protein farnesyltransferase shows approved-linked disease relevance led by Hutchinson-Gilford progeria syndrome. 5 more disease programs remain visible in the same review block.
Start review with Hutchinson-Gilford progeria syndrome because it currently carries approved-linked support. Linked drugs include LONAFARNIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL361246 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL525369 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL426063 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL128501 | 10.44 | IC50 | 0.036 | Preclinical |
| CHEMBL294888 | 10.22 | IC50 | 0.06 | Preclinical |
| CHEMBL310586 | 10.22 | IC50 | 0.06 | Preclinical |
| CHEMBL4565280 | 10.22 | IC50 | 0.06 | Preclinical |
| CHEMBL23578 | 10.1 | IC50 | 0.079 | Preclinical |
| CHEMBL379900 | 10.1 | IC50 | 0.08 | Preclinical |
| CHEMBL378462 | 10.05 | IC50 | 0.09 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 271 | 1,816 | 7.0 |
| cell-based format | 31 | 156 | 7.0 |
| assay format | 18 | 75 | 6.7 |
| organism-based format | 1 | 5 | 5.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 35 | 147 | 7.3 |
| assay format | 20 | 94 | 7.7 |